

**NOTICE OF NEW HAMPSHIRE MEDICAID FEE FOR SERVICE
DRUG UTILIZATION REVIEW BOARD
PUBLIC HEARING
December 15, 2020**

The New Hampshire Drug Utilization Review (DUR) Board invites you to attend a public hearing at 2:00 p.m., on December 15, 2020 via Zoom Conference. The DUR meeting will immediately follow this public hearing. The Zoom Conference information will be available 1 week prior to the DUR meeting at

<https://www.dhhs.nh.gov/ombp/pharmacy/notices.htm>

and

<https://newhampshire.magellanmedicaid.com/portal/spring/public/nhportalpublic?execution=e1s1> .

The purpose of the public hearing is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid Fee for Service pharmacy prior authorization criteria and preferred drug list (PDL) class additions.

The public hearing will begin at 2:00 p.m. and end no later than 3:00 p.m. The DUR meeting will begin at or before 3:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the proposed prior authorization criteria and PDL additions. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda as they relate to the prior authorization criteria and PDL class additions.

Written material may also be submitted by the public for DUR Board consideration, if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

If accommodations are needed for communication access such as interpreters, CART (captioning), assistive listening devices, or other auxiliary aids and/or services, please contact Nancy Plourde at (603) 271-9422 by November 30, 2020. At least 5 business days advance notice is requested in order to assure availability; requests made fewer than 5 days prior to the event will attempt to be accommodated but cannot be guaranteed.

**DRUG UTILIZATION REVIEW BOARD MEETING
December 15, 2020
Meeting Agenda**

- I. Introductions and Welcome to Board Members

- II. Old Business
 - A. Minutes – 6/30/20 review

- III. New Business
 - A. DUR Business Operations

1. Overview of Drug Utilization Patterns for the New Hampshire Medicaid Fee-for-Service Program
 - a. Prospective DUR Reports
 - b. Utilization Reports
 - c. Retrospective DUR Reports

B. COVID-19 Status Update

C. Review of Current Clinical Prior Authorization Criteria with Proposed Changes

1. Anti-Fungal Medication for Onychomycosis
2. Anti-Obesity
3. Atopic Dermatitis
4. Buprenorphine/Naloxone and Buprenorphine (Oral)
5. Carisoprodol and Combination Medication
6. Calcitonin Gene-Related Peptide (CGRP) Inhibitor
7. Duloxetine
8. Dupixent®
9. Hepatitis C
10. Hyaluronic Acid Derivatives – Injection
11. Long-Acting Opioid Analgesics
12. Lyrica®
13. Methadone (Pain Management Only)
14. Morphine Milligram Equivalent
15. Movement Disorders
16. Oral Isotretinoin
17. Oral NSAIDs and Combinations Legend (Rx Required)Systemic
18. Immunomodulators
19. Topical NSAIDs Legend (Rx Required)

D. Review of Current Clinical Prior Authorization Criteria with No Proposed Changes

1. Brand Name Multiple Source Prescription Drug Product
2. Fibromyalgia
3. Human Growth Hormones
4. Inhaled Insulin
5. New Drug Product
6. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
7. Psychoactive Medication for Children (5 Years of Age or Younger)
8. Psychotropic Medication Duplicate Therapy (Patients 6 Years and Older)
9. Restless Leg Syndrome
10. Symlin®
11. Synagis®
12. Zolgensma®

E. Proposal of New Clinical Prior Authorization Criteria

1. Adenosine triphosphate-citrate lyase (ACL) inhibitor
2. Spravato®

3. Duchenne Muscular Dystrophy Agents

F. Proposal of New Preferred Drug List (PDL) Category

1. Glucagon Agents
2. Movement Disorders
3. Potassium Binders

IV. Adjourn

Further information regarding the agenda items may be obtained after November. 30, 2020. Notice of intent to testify at the public hearing, and/or submittal of written comments, should be directed to Nancy Plourde, NH Department of Health and Human Services, 129 Pleasant Street, Concord, NH, 03301, (603) 271-9422, or e-mail at: nancy.t.plourde@dhhs.nh.gov.